• Innovative Approaches for Personalised Cardiovascular Prevention

  NCT05883878

  RecruitingInterventionalNot ApplicableUpdated Aug 22, 2025
• Personalised HeartCare: Poligenic Risk Scores Disclosure for Cardiovascular Prevention

  NCT06888466

  RecruitingInterventionalNot ApplicableUpdated Feb 20, 2026
• The Effect of a Digital Heart Health App and Lifestyle Intervention for Heart Disease in Primary Care.

  NCT06919302

  RecruitingInterventionalNot ApplicableUpdated Nov 26, 2025
• Polygenic Risk Score for Optimizing Primary Prevention in Intermediate-Risk Populations

  NCT07039123

  Active, not recruitingInterventionalNot ApplicableUpdated Jun 30, 2026
• Italian Digital Primary Cardiovascular Prevention Study

  NCT05339841

  Active, not recruitingInterventionalNot ApplicableUpdated Apr 4, 2025
• Proactive Cardiovascular Prevention Strategy in Subjects With High Genetic Risk

  NCT04291157

  Unknown statusInterventionalNot ApplicableUpdated Mar 2, 2020

ClinicalTrials.gov ID

NCT06911294

Lead Sponsor

Catholic University of the Sacred HeartOTHER

Overall Status

Recruiting

Study Type

Interventional

Phase

Not Applicable

Enrollment

120Estimated

Last Update Posted

Aug 5, 2025Actual

Start Date

Feb 10, 2025Actual

Primary Completion Date

Feb 10, 2026Estimated

Completion Date

Sep 10, 2026Estimated

Official Title

Feasibility of InnovaTive Approaches for Personalized Cardiovascular PREVention: Randomized Controlled Pilot Trial and Multidisciplinary Evaluation for National Health Service Implementation

Brief Summary

The goal of the FITPREV (Feasibility of InnovaTive approaches for personalized cardiovascular PREVention: randomized controlled pilot trial and multidisciplinary evaluation for National Health Service implementation) clinical trial is to study the feasibility of innovative approaches( Polygenic Risk Score and health smartwatch) for personalized primary preventive interventions in cardiovascular diseases (CVD). The main questions it aims to answer are:

• Feasibility of a greater study.
• Feasibility of the interventions in a realistic setting, such as the medical office of a General Practitioner.

Participants will be randomized in one of the four parallel arms:

• standard of care;
• genetic testing for cardiovascular genetic risk (through the cardiovascular Polygenic Risk Score or PRS);
• digital intervention with a wearable device and its app;
• digital intervention and genetic testing

The primary outcomes that are going to be evaluated are patient's and General Practitioners' overall judgment of the study and its feasibility.

Secondarily the efficacy of returning Polygenic Risk Score (PRS) results will be assessed. This will happen on two endpoints: i) change in lifestyle pattern; ii) CVD risk profile modification. The postulated hypothesis is that the achievement of these endpoints is more likely in presence of at least one of the aforementioned interventions than among subjects who receive only traditional risk assessment at baseline.

Detailed Description

This study aims to evaluate the feasibility and secondarily efficacy of disclosing cardiovascular genetic risk-in the setting of a general practitioner's office-in the promotion of healthier lifestyle behaviors.

The enrollment period will last 6 months, with each participant taking part in the study for 12. There are three key time points in the study, T0 or baseline (enrollment phase), T1 or disclosure visit after one month, T2 intermediate visit(after six months) and T3 or final visit at 12 months. At enrollment, participants will be classified into risk categories based on cardiovascular risk using the SCORE-2 or SCORE 2-OP tool. Individuals aged 40-69, without diabetes or congenital hypercolesterolemia, with a SCORE-2 between 2.5% and 10% and a diagnosys of metabolic syndrome according to the American Hearth Association Criteria will be enrolled.

Once enrolled (T0), all participants will sign the informed consent form and undergo a comprehensive assessment, which includes:

• Completing a questionnaire on socioeconomic status, area of residence, and lifestyle, using the Life's Essential 8 tool. The questionnaire will cover smoking status, alcohol consumption, dietary pattern, sleep pattern, and physical activity. Participants will be classified into favorable, intermediate, or unfavorable individual lifestyle patterns according to the Life's Essential 8 score.
• Blood analysis will be performed to evaluate the lipid profile, including total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides.

At T1, a disclosure visit will be conducted to explain the assigned lifestyle category, share the results of the blood tests, and provide information on the expected interventions based on the assigned group.

The questionnaire will be administered at T0, T2, and T3. Blood analysis and cardiovascular profile evaluation will be conducted at both T0 and T3.

Feasibility Questionnaire: Both participants and medical professionals will complete a questionnaire on the acceptability and feasibility of the intervention.

• Coronary Heart Disease

• Polygenic Risk Score
• Digital app and wearable device

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

Yes

Eligibility Criteria

Inclusion Criteria:

• Age 40-69 years;

• 10 year cardiovascular risk score SCORE2 between 2.5% and 10%.

• Diagnosis of metabolic syndrome according to the American Heart Association criteria , defined as the presence of three or more of the following:

  • Central or abdominal obesity, measured by waist circumference (greater than 40 inches - 102 cm in men and 35 inches - 89 cm in women).
  • Elevated triglycerides: levels equal to or greater than 150 mg/dL or use of medication for hypertriglyceridemia.
  • Low HDL cholesterol levels (less than 40 mg/dL in men and less than 50 mg/dL in women) or use of cholesterol-lowering medication.
  • Elevated blood pressure: systolic ≥130 mmHg or diastolic ≥85 mmHg, or use of antihypertensive medication.
  • Elevated fasting blood glucose: ≥100 mg/dL or use of glucose-lowering medication.

Exclusion Criteria:

• Diabetes:
• Familial hypercholesterolemia;
• Previous cardiovascular events.

Primary Purpose

Prevention

Allocation

Randomized

Interventional Model

Parallel Assignment

Masking

None (Open Label)

Lead Sponsor

Catholic University of the Sacred HeartOTHER

dr.collettimg@gmail.com+393933062969

enricamaggiori@libero.it+393392334787

massimo.mammucari@libero.it+393357685440

giuliaantonia.marra@gmail.com3489312237

filippopaoletti.an@gmail.com+393336479293

giuliofm.pasca@gmail.com+393484267755